4 research outputs found
Wp艂yw oligomer贸w procyanidolowych na aktywno艣膰 antykoagulacyjn膮 osocza
Background. Procyanidolic oligomers (PO) inhibit the degradation of subendothelial
connective tissue by collagenase and elastase neutralization. Their efficacy in
postphlebitic syndrome and venous insufficiency may suggest an additional systemic
action mediated by endothelium. Therefore, the plasma anticoagulant response and
the tissue plasma pathway inhibitor (TFPI) release induced by PO was assessed.
Material and methods. Twenty-six patients, both surgical and medical, aged
29–86 years, who required antithrombotic prophylaxis for at least 5 days, were
included in the study. The patients with higher thrombotic risk received either
unfractionated heparin (UFH; 5000 IU bid, s.c., n = 8) or low molecular weight
heparin (LMWH; 2850 IU AXa/0.3 mL o.d, s.c., n = 8). The patients with lower thrombotic
risk received PO (150 mg bid, p.o., n = 10). In the control group there were age-
and sex-matched healthy volunteers, to whom a placebo was administered. Blood
samples were drawn before, on the 1, 4, 8 h, as well as on the days 2, 5 after
administration of the study medication.
Results. The TFPI concentration did not change significantly from the baseline
value at any time, either in patients or in controls. Anti-Xa activity increased
at 1 h until day 5 after administration of each study medication. Anti-IIa activity
increased at 1 hour and remained elevated until day 5 under UFH and LMWH treatment,
but only until day 2 in the PO group. The area under the curve of both anti-Xa
and anti-IIa activity was similar in all three study groups but significantly
larger as compared to the controls.
Conclusions. Procyanidolic oligomers, like heparin and LMWH, induce anticoagulant
response in plasma, but do not release TFPI into the blood.Wst臋p. Oligomery procyanidolowe (PO) hamuj膮 degradacj臋 pod艣r贸db艂onkowej
tkanki 艂膮cznej poprzez neutralizacj臋 kolagenazy i elastazy. Skuteczno艣膰 PO w zespole
pozakrzepowym i niewydolno艣ci 偶ylnej mo偶e sugerowa膰 ich dodatkowe dzia艂anie uk艂adowe,
w kt贸rym po艣redniczy 艣r贸db艂onek. By艂o to przes艂ank膮 do oceny odpowiedzi antykoagulacyjnej
osocza wywo艂ywanej przez PO i uwalniania inhibitora drogi zewn膮trzpochodnej (TFPI).
Materia艂 i metody. Do badania w艂膮czono 26 chorych z oddzia艂贸w chirurgicznego
i internistycznego w wieku 29–86 lat, u kt贸rych konieczne by艂o zastosowanie profilaktycznej
terapii przeciwzakrzepowej przez co najmniej 5 dni. Chorzy z du偶ym ryzykiem zakrzepowym
otrzymywali albo heparyn臋 niefrakcjonowan膮 (UFH; 5000 jm. dwa razy dziennie podsk贸rnie,
n = 8), albo heparyn臋 drobnocz膮steczkow膮 (LMWH; 2850 jm. AXa/0,3 ml raz dziennie
podsk贸rnie, n = 8). Pacjenci, u kt贸rych ryzyko zakrzepowe by艂o ma艂e, otrzymywali
PO (150 mg dwa razy dziennie doustnie, n = 10). Grup臋 kontroln膮 stanowili zdrowi
ochotnicy zaklasyfikowani wed艂ug wieku i p艂ci, otrzymuj膮cy placebo. Krew do bada艅
pobierano przed podaniem leku oraz w 1., 4. i 8. godzinie oraz w 2. i 5. dniu od podania leku.
Wyniki. St臋偶enie TFPI nie zmienia艂o si臋 w por贸wnaniu z warto艣ci膮 wyj艣ciow膮
zar贸wno w grupach badanych, jak i kontrolnej. Aktywno艣膰 anty-Xa zwi臋ksza艂a si臋 od 1. godziny do 5. dnia po podaniu ka偶dego leku. Aktywno艣膰 anty-IIa by艂a zwi臋kszona
od 1. godziny do 5. dnia po podaniu UFH i LMWH, ale tylko do 2. dnia po PO. Ca艂kowita aktywno艣膰 anty-Xa i anty-IIa, oceniana jako wielko艣膰 pola pod krzyw膮 w badanym
czasie, by艂a podobna we wszystkich grupach badanych, ale znacz膮co wy偶sza w por贸wnaniu
z grup膮 kontroln膮.
Wnioski. Oligomery procyanidolowe, podobnie jak heparyna niefrakcjonowana
i drobnocz膮steczkowa, wywo艂uj膮 odpowied藕 antykoagulacyjn膮 w osoczu, ale nie powoduj膮
uwalniania TFPI do krwi
Profound thrombocytopenia after abciximab administration in acute myocardial infarction and stent thrombosis following thrombocytopenia remission - a case report
Profound thrombocytopenia after abciximab administration in acute myocardial infarction and stent thrombosis: This article presents a case of a 62-years-old man with acute anterior myocardial infarction, treated with PCI and stent implantation, in whom profound acute thrombocytopenia was observed after abciximab administration. Nadir platelet count was 6 G/L (before treatment: 250 G/L). Pseudothrombocytopenia was excluded. The remaining antiplatelet drugs (heparin, ASA, clopidogrel) were discontinued. There were no symptoms of bleeding, but next morning (platelet count: 14 G/L) a gross hematoma at femoral puncture site was observed. The patient received 5 U transfusion of platelets. On the 4th day, when the platelet count reached 64 G/L, he was started again on ASA (150 mg) and clopidogrel (75 mg). On the 7th day (platelet count: 138 G/L) he developed anterior ischemia and stent reocclusion was diagnosed. After p.o. clopidogrel (300 mg), balloon PCI with i.c. heparin was performed and ischemia symptoms subsided. The platelet value before the patient's discharge, on subsequent therapy with ASA and clopidogrel, increased to 300 G/L. A review of current literature on this topic is provided
Elevation of plasma fibrinogen in silent myocardial ischaemia
High plasma levels of fibrinogen and plasminogen activator inhibitor (PAI-1) are reported to be correlated with coronary heart disease. Therefore the level of fibrinogen concentration in plasma was examined and verified for the possible correlation with the previously explored PAI-1 antigen and PAI-1 activity in the pathogenesis of premature atherosclerosis (Grzywaczet al., 1998,Blood Coagul Fibrinol. 9, 245-249). Examination included only men, aged 33-46 years, who were in a stable condition for at least six months after the acute event. They were divided into two subgroups: group A (n聽=聽14) 聽with and group B (n = 15) without ischaemic changes in 24 h Holter electrocardiogram. The number of involved vessels visible on the coronarography picture was similar in both groups. In the patients of group A the mean level of fibrinogen (3.92 vs 3.23 g/l, P < 0.05) was higher than in the controls (n = 15). No statistically differences were found between group B and control healthy subjects in any of the parameters measured. There were no correlation between fibrinogen concentration and PAI-1 antigen and activity levels, which were elevated in both groups of patients according to our previous study. Our results indicate that elevated levels of plasma fibrinogen and PAI-1 appeared in the group of patients with more severe disease, as revealed by silent myocardial ischaemia
Case reportMassive pulmonary embolism in a patient with ulcerative colitis and hyperhomocysteinemia – a case report
We describe a case of a 37-year-old man with active ulcerative colitis complicated by proximal deep vein thrombosis of the left lower limb and subsequent massive pulmonary embolism requiring mechanical ventilation and catecholamine infusion. In spiral CT a large thrombus obturating left pulmonary artery as well as bilateral embolic material in lobar and segmental branches were visible. Haemodynamic status improved after infusion of rtPA. Haemoglobin decrease (7.0–5.6 mmol/L) was corrected with erythrocyte mass transfusion. During subsequent therapy with intravenous full dose of unfractionated heparin and further long-term treatment with subcutaneous enoxaparin (1.5 mg/kg and after 3 months 1.0 mg/kg daily) haemoglobin value was relatively stable. Underlying disease was treated with 5-ASA (mesalazine) and steroids. Due to hyperhomocysteinaemia (16.0 µmol/L) coexisting with a low plasma folic acid (2.1 ng/ml) and cyanocobalamin (137 pg/ml) levels, supplementation with these vitamins was prescribed. The screening tests for familial thrombophilia (including 677C→T MTHFR mutation) were negative. The authors discuss the pathogenesis of increased thromboembolic risk in inflammatory bowel disease and therapeutic dilemmas connected with treatment of such complications